Acid-induced aggregation propensity of nivolumab is dependent on the Fc. Issue 6 (17th August 2016)

• Record Type: Journal Article
• Authors: Liu, Boning; Guo, Huaizu; Xu, Jin; Qin, Ting; Xu, Lu; Zhang, Junjie; Guo, Qingcheng; Zhang, Dapeng; Qian, Weizhu; Li, Bohua; Dai, Jianxin; Hou, Sheng; Guo, Yajun; Wang, Hao
• Is Part Of: MAbs. Volume 8:Issue 6(2016)
• Page Start: 1107
• Page End: 1117
• Publication Date: 2016-08-17
• Subjects: Acid-induced aggregates -- atezolizumab -- Fc -- IgG4 subclass -- nivolumab -- panitumumab -- Protein A chromatography -- purification process -- tocilizumab -- viral inactivation; Monoclonal antibodies -- Therapeutic use -- Periodicals; Monoclonal antibodies -- Periodicals; Antibodies, Monoclonal -- Periodicals; 616.0798
• DOI: 10.1080/19420862.2016.1197443
• Languages: English
• ISSNs: 1942-0862

Abstract

ABSTRACT: Nivolumab, an anti-programmed death (PD)1 IgG4 antibody, has shown notable success as a cancer treatment. Here, we report that nivolumab was susceptible to aggregation during manufacturing, particularly in routine purification steps. Our experimental results showed that exposure to low pH caused aggregation of nivolumab, and the Fc was primarily responsible for an acid-induced unfolding phenomenon. To compare the intrinsic propensity of acid-induced aggregation for other IgGs subclasses, tocilizumab (IgG1 ), panitumumab (IgG2 ) and atezolizumab (aglyco-IgG1 ) were also investigated. The accurate pH threshold of acid-induced aggregation for individual IgG Fc subclasses was identified and ranked as: IgG1 < aglyco-IgG1 < IgG2 < IgG4 . This result was cross-validated by thermostability and conformation analysis. We also assessed the effect of several protein stabilizers on nivolumab, and found mannitol ameliorated the acid-induced aggregation of the molecule. Our results provide valuable insight into downstream manufacturing process development, especially for immune checkpoint modulating molecules with a human IgG4 backbone.